This module uses fundamental data of Sonoma Pharmaceuticals to approximate its Piotroski F score. Sonoma Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Sonoma Pharmaceuticals. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Sonoma Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Sonoma Pharmaceuticals Altman Z Score, Sonoma Pharmaceuticals Correlation, Sonoma Pharmaceuticals Valuation, as well as analyze Sonoma Pharmaceuticals Alpha and Beta and Sonoma Pharmaceuticals Hype Analysis.
At present, Sonoma Pharmaceuticals' Short and Long Term Debt Total is projected to decrease significantly based on the last few years of reporting. The current year's Short Term Debt is expected to grow to about 781 K, whereas Net Debt is forecasted to decline to (2.6 M). At present, Sonoma Pharmaceuticals' PTB Ratio is projected to increase slightly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 0.24, whereas Price To Sales Ratio is forecasted to decline to 0.10.
At this time, it appears that Sonoma Pharmaceuticals' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Sonoma Pharmaceuticals is to make sure Sonoma is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Sonoma Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Sonoma Pharmaceuticals' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Sonoma Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Sonoma Pharmaceuticals in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
12.83
At present, Sonoma Pharmaceuticals' Book Value Per Share is projected to decrease significantly based on the last few years of reporting.
Sonoma Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sonoma Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sonoma Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social
About Sonoma Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sonoma Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sonoma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sonoma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:
For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.99)
Revenue Per Share
20.967
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.20)
Return On Equity
(0.75)
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.